Search

Your search keyword '"Baracos, Vickie E."' showing total 887 results
Start Over Author "Baracos, Vickie E."
887 results on '"Baracos, Vickie E."'

10. Sarcopenia: A Time for Action. An SCWD Position Paper

Author

Bauer, Juergen, Morley, John E, Schols, Annemie MWJ, Ferrucci, Luigi, Cruz‐Jentoft, Alfonso J, Dent, Elsa, Baracos, Vickie E, Crawford, Jeffrey A, Doehner, Wolfram, Heymsfield, Steven B, Jatoi, Aminah, Kalantar‐Zadeh, Kamyar, Lainscak, Mitja, Landi, Francesco, Laviano, Alessandro, Mancuso, Michelangelo, Muscaritoli, Maurizio, Prado, Carla M, Strasser, Florian, Haehling, Stephan, Coats, Andrew JS, and Anker, Stefan D

Subjects
Nutrition, Biomedical Imaging, Prevention, Aging, Musculoskeletal, Disease Management, Disease Susceptibility, Humans, Practice Guidelines as Topic, Sarcopenia, Cachexia, Geriatric assessment, Muscle, Skeletal, Muscle strength, Physiology, Clinical Sciences, Human Movement and Sports Sciences
Abstract

The term sarcopenia was introduced in 1988. The original definition was a "muscle loss" of the appendicular muscle mass in the older people as measured by dual energy x-ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC-F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease-related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age-related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age-related and disease-related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life-long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.

Published
2019

16. Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.

Author

Brown, Leo R., Sousa, Mariana S., Yule, Michael S., Baracos, Vickie E., McMillan, Donald C., Arends, Jann, Balstad, Trude R., Bye, Asta, Dajani, Olav, Dolan, Ross D., Fallon, Marie T., Greil, Christine, Hjermstad, Marianne J., Jakobsen, Gunnhild, Maddocks, Matthew, McDonald, James, Ottestad, Inger O., Phillips, Iain, Sayers, Judith, and Simpson, Melanie R.

Published
2024
Full Text
View/download PDF

18. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer

Author

Parsons, Henrique A, Baracos, Vickie E, Hong, David S, Abbruzzese, James, Bruera, Eduardo, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pancreatic Cancer, Nutrition, Cancer, Rare Diseases, Digestive Diseases, Complementary and Integrative Health, Clinical Research, Antineoplastic Agents, Body Composition, Body Weight, Case-Control Studies, Curcumin, Female, Follow-Up Studies, Humans, Male, Middle Aged, Muscle, Skeletal, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Subcutaneous Fat, Survival Rate, pancreatic neoplasms, curcumin, body composition, inflammation, Oncology and carcinogenesis
Abstract

BackgroundCurcumin is a natural product that is often explored by patients with cancer. Weight loss due to fat and muscle depletion is a hallmark of pancreatic cancer and is associated with worse outcomes. Studies of curcumin's effects on muscularity show conflicting results in animal models.Methods and resultsRetrospective matched 1:2 case-control study to evaluate the effects of curcumin on body composition (determined by computerized tomography) of 66 patients with advanced pancreatic cancer (22 treated,44 controls). Average age (SEM) was 63(1.8) years, 30/66(45%) women, median number of prior therapies was 2, median (IQR) time from advanced pancreatic cancer diagnosis to baseline image was 7(2-13.5) months (p>0.2, all variables). All patients lost weight (3.3% and 1.3%, treated vs. control, p=0.13). Treated patients lost more muscle (median [IQR] percent change -4.8[-9.1,-0.1] vs. -0.05%[-4.2, 2.6] in controls,p

Published
2016

26. The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey

Author

Naito, Tateaki, primary, Wakabayashi, Hidetaka, additional, Aso, Sakiko, additional, Konishi, Masaaki, additional, Saitoh, Masakazu, additional, Baracos, Vickie E., additional, Coats, Andrew J., additional, Anker, Stefan D., additional, Sherman, Lawrence, additional, Klompenhouwer, Tatiana, additional, Shirotani, Noriyasu, additional, Inui, Akio, additional, and Arai, Hidenori, additional

Published
2023
Full Text
View/download PDF

32. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service.

Author

Parsons, Henrique A, Baracos, Vickie E, Dhillon, Navjot, Hong, David S, and Kurzrock, Razelle

Subjects
Humans, Neoplasms, Neoplasm Staging, Multivariate Analysis, Survival Analysis, Body Composition, Middle Aged, Referral and Consultation, Female, Male, Clinical Trials, Phase I as Topic, Clinical Trials, Phase I as Topic, General Science & Technology
Abstract

BackgroundBody weight and body composition are relevant to the outcomes of cancer and antineoplastic therapy. However, their role in Phase I clinical trial patients is unknown.MethodsWe reviewed symptom burden, body composition, and survival in 104 patients with advanced cancer referred to a Phase I oncology service. Symptom burden was analyzed using the MD Anderson Symptom Assessment Inventory(MDASI); body composition was evaluated utilizing computerized tomography(CT) images. A body mass index (BMI)≥25 kg/m² was considered overweight. Sarcopenia, severe muscle depletion, was assessed using CT-based criteria.ResultsMost patients were overweight (n = 65, 63%); 53 patients were sarcopenic (51%), including 79% of patients with a BMI

Published
2012

33. TITAN Trial

Author

Kirkham, Amy A., primary, Mackey, John R., additional, Thompson, Richard B., additional, Haykowsky, Mark J., additional, Oudit, Gavin Y., additional, McNeely, Margaret, additional, Coulden, Richard, additional, Stickland, Michael K., additional, Baracos, Vickie E., additional, Dyck, Jason R.B., additional, Haennel, Robert, additional, Pituskin, Edith, additional, and Paterson, D. Ian, additional

Published
2023
Full Text
View/download PDF

39. Cancer-associated malnutrition

Author

Baracos, Vickie E.

Subjects
Malnutrition -- Risk factors -- Care and treatment, Cancer treatment -- Complications and side effects -- Methods, Nutritional assessment -- Methods, Cancer research, Jurisdiction, Disease susceptibility, Cancer, Universities and colleges, Cancer patients, Food/cooking/nutrition, Health
Abstract

Author(s): Vickie E. Baracos [sup.1] Author Affiliations: (1) Department of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Avenue Edmonton, Alberta, Canada What is already known about cancer-associated malnutrition? [...]

Published
2018
Full Text
View/download PDF

45. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy

Author

Panje, Cédric M., Höng, Laura, Hayoz, Stefanie, Baracos, Vickie E., Herrmann, Evelyn, Garcia Schüler, Helena, Meier, Urs R., Henke, Guido, Schacher, Sabina, Hawle, Hanne, Gérard, Marie-Aline, Ruhstaller, Thomas, Plasswilm, Ludwig, and for the Swiss Group for Clinical Cancer Research (SAKK)

Published
2019
Full Text
View/download PDF

49. A Multi-Site, International Audit of Malnutrition Risk and Energy and Protein Intakes in Patients Undergoing Treatment for Head Neck and Esophageal Cancer: Results from INFORM

Author

Martin, Lisa, primary, Findlay, Merran, additional, Bauer, Judith D., additional, Dhaliwal, Rupinder, additional, de van der Schueren, Marian, additional, Laviano, Alessandro, additional, Widaman, Adrianne, additional, Baracos, Vickie E., additional, Day, Andrew G., additional, and Gramlich, Leah M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results